Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.35 |
| ▸ | LPL | P06858 | 4/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | TACR2 | P21452 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196176 | 0.92 | ALDH1A1 (0.33) | MEN1KMT2AALDH1A1 | |
| SCHEMBL11241470 | 0.90 | ALDH1A1 (0.32) | MEN1KMT2AALDH1A1 | |
| SCHEMBL707695 | 0.85 | — | — | |
| SCHEMBL8773639 | 0.83 | — | — | |
| SCHEMBL17666834 | 0.81 | — | — | |
| SCHEMBL14861960 | 0.81 | — | — | |
| SCHEMBL333316 | 0.73 | — | — | |
| SCHEMBL5489477 | 0.73 | TSHR (0.42) | LIPGLPLESR1ADRA2AADORA3 | |
| SCHEMBL11254990 | 0.72 | — | — | |
| SCHEMBL7761576 | 0.69 | MEN1 (0.42) | MEN1KMT2ALIPGLPLTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040030093-A1 | Metal catalyst for ring-opening polymerization of heterocyclic compound | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| EP-1340780-A1 | METAL CATALYST FOR RING-OPENING POLYMERIZATION OF HETEROCYCLIC COMPOUND | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030093-A1 | Metal catalyst for ring-opening polymerization of heterocyclic compound | MAX, PCNA, POLM | MEN1 830/4885KMT2A 1146/4885LIPG 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.